The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2020 | The assets of MRD in myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses three important assets of measurable residual disease (MRD) in multiple myeloma. First that MRD has emerged as one of the most relevant diagnostic factors for myeloma. Second, that undetectable MRD in a significant proportion of patients could become a treatment endpoint. Third, that MRD response will be a surrogate for survival and a potential biomarker. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
